Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
TALS Talaris Therapeutics
1.630-0.140-7.91%
Close
02/03 16:00 ET
1.6300.0000.00%
Post Mkt Price 02/03 16:03 ET
High
1.760
Open
1.710
Turnover
476.46K
Low
1.620
Pre Close
1.770
Volume
283.55K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Talaris Therapeutics (NASDAQ:TALS) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reissued their buy rating on shares of Talaris Therapeutics (NASDAQ:TALS – Get Rating) in a research note published on Monday morning, Benzinga reports. They currently have a $12.00 ta
Q4 2022 EPS Estimates for Talaris Therapeutics, Inc. Cut by HC Wainwright (NASDAQ:TALS)
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) – Stock analysts at HC Wainwright decreased their Q4 2022 earnings per share estimates for Talaris Therapeutics in a report released on Monday
Talaris Therapeutics (TALS) Gets a Buy From H.C. Wainwright
Talaris Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Talaris Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/30/2023 795.52% HC Wainwright & Co. → $12 Reiterates → Buy 10/24/2022 795.52% HC Wainwright & Co. $18 →
HC Wainwright & Co. Reiterates Buy on Talaris Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Talaris Therapeutics (NASDAQ:TALS) with a Buy and maintains $12 price target.
Contrasting Talaris Therapeutics (NASDAQ:TALS) & Pluri (NASDAQ:PLUR)
Talaris Therapeutics (NASDAQ:TALS – Get Rating) and Pluri (NASDAQ:PLUR – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on t
Stocks That Hit 52-Week Lows On Tuesday
 Tuesday's session saw 325 companies set new 52-week lows. 52-Week Low Highlights: Apple (NASDAQ:AAPL) was the biggest company in terms of market cap to set a new 52-week low.InMed Pharmaceuticals
Talaris Therapeutics (NASDAQ:TALS) Shares Down 0.9%
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) shares were down 0.9% during mid-day trading on Monday . The stock traded as low as $1.08 and last traded at $1.10. Approximately 2,842 shares ch
We Think Talaris Therapeutics (NASDAQ:TALS) Needs To Drive Business Growth Carefully
Company Overview
More
Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Louisville, KY.
CEO： Mr. Scott Requadt
Market： NASDAQ
Listing Date： 05/07/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet